FLT3 Inhibitors in Acute Myeloid Leukemia

FMS related tyrosine kinase 3 (FLT3) is a frequently mutated receptor tyrosine kinase in Acute Myeloid Leukemia. Novel Tyrosine kinase inhibitors against FLT3 are currently in clinical trial. Discover the latest research on FLT3 Inhibitors in Acute Myeloid Leukemia here.

May 23, 2020

Development of a novel and quick UPLC-MS/MS method for the pharmacokinetic analysis of duvelisib in beagle dogs

Journal of Pharmaceutical and Biomedical Analysis
Yuanyuan ShaoRen-Ai Xu
July 1, 2020

Targeted informatics for optimal FLT3-ITD detection, characterization, and quantification across multiple NGS platforms

The Journal of Molecular Diagnostics : JMD
Harrison K TsaiValentina Nardi
May 23, 2020
Open Access

Lestaurtinib potentiates TRAIL-induced apoptosis in glioma via CHOP-dependent DR5 induction

Journal of Cellular and Molecular Medicine
Yingxiao CaoYanhui Qi
May 28, 2020
Open Access

FLT3-ITD DNA and mRNA levels in AML do not correlate with CD7, CD33 and CD123 expression

Journal of Cellular and Molecular Medicine
Dan-Sebastian SoareAna Maria Vlădăreanu
June 18, 2020
Open Access

Gilteritinib in the treatment of relapsed and refractory acute myeloid leukemia with a FLT3 mutation

Therapeutic Advances in Hematology
Serena ChewElias Jabbour
June 11, 2020
Open Access

Characterization of a Novel FLT3 BiTE® Antibody Construct for the Treatment of Acute Myeloid Leukemia

Molecular Cancer Therapeutics
Bettina BrauchleTara Arvedson
June 20, 2020

Analysis of Genomic Landscape in Patients with Acute Myeloid Leukemia

Zhongguo shi yan xue ye xue za zhi
Sheng-Mei WangJin-Hua Yao
May 20, 2020

Azacytidine in Newly Diagnosed FLT3-ITD-Positive Acute Myeloid Leukemia Presenting with Pneumonia: A Case Series

Indian Journal of Hematology & Blood Transfusion : an Official Journal of Indian Society of Hematology and Blood Transfusion
Santosh Raut KurmiRahul Bhargava
May 19, 2020

FLT3 Inhibition in Acute Myeloid Leukaemia - Current Knowledge and Future Prospects

Current Cancer Drug Targets
Francesca L HoganSteven Knapper
May 13, 2020
Case Report
Open Access

Isavuconazole Therapy of Disseminated and Encephalic Saprochaete Capitata Infection in an Acute Myeloid Leukemia Patient Treated with Midostaurin

Mediterranean Journal of Hematology and Infectious Diseases
Salvatore PerroneGiuseppe Cimino
May 27, 2020

New drugs in gastrointestinal stromal tumors

Current Opinion in Oncology
Javier Martin-Broto, David S Moura
June 10, 2020
Open Access

Antifungal prophylaxis and novel drugs in acute myeloid leukemia: the midostaurin and posaconazole dilemma

Annals of Hematology
Jannik StemlerOliver A Cornely
June 1, 2020

Outcome of Childhood Acute Myeloid Leukemia With FLT3-ITD Mutation: The Experience of Children's Cancer Hospital Egypt, 2007-17

Clinical Lymphoma, Myeloma & Leukemia
Samah Fathy SemarySonia Mahmoud

Sign up to follow this feed and discover related papers.

Related Feeds

Acute Myeloid Leukaemia & RNA

Acute myeloid leukaemia (AML) is a common hematological type of cancer. As the population ages, there has been a rise in the frequency of AML. RNA expression has been used to see if there are different genetic profiles that exist within AML and whether these may underpin the variations in survival rates. Here is the latest research on AML and RNA.

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.

Angiogenesis Inhibitors to Treat Cancer

Cancer treatments including angiogenesis inhibitors prevent tumor cells from receiving nutrients and oxygen. Here is the latest research on angiogenesis inhibitors for the treatment of cancer.

Autoimmune Lymphoproliferative Syndrome

Autoimmune lymphoproliferative syndrome (ALPS) is a rare genetic disorder of abnormal lymphocyte survival caused by defective Fas mediated apoptosis. Discover the latest research on ALPS here.

B-Cell Lymphoma

B-cell lymphomas include lymphomas that affect B cells. This subtype of cancer accounts for over 80% of non-Hodgkin lymphomas in the US. Here is the latest research.

Biosensors for Cancer Detection

Biosensors are devices that are designed to detect a specific biological analyte by essentially converting a biological entity (ie, protein, DNA, RNA) into an electrical signal that can be detected and analyzed. The use of biosensors in cancer detection and monitoring holds vast potential. Biosensors can be designed to detect emerging cancer biomarkers and to determine drug effectiveness at various target sites. Biosensor technology has the potential to provide fast and accurate detection, reliable imaging of cancer cells, and monitoring of angiogenesis and cancer metastasis, and the ability to determine the effectiveness of anticancer chemotherapy agents.

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.

Bone Marrow Neoplasms

Bone Marrow Neoplasms are cancers that occur in the bone marrow. Discover the latest research on Bone Marrow Neoplasms here.

Breast Cancer: Chemo-Resistance

Some cancers are difficult to treat and aggressive including the "triple-negative" breast cancer. This type of cancer is chemoresistant even before chemotherapy begins. Here are the latest discoveries chemo-resistance in breast cancer.

CAR-T cells

Chimeric antigen receptor (CAR) T cells are cells that are genetically engineered to recognize and target specific proteins. The ability of these cells to recognize cancer antigens and eliminate tumor cells have transformed cancer immunotherapy approaches. Here is the latest research on CAR-T cells.

© 2020 Meta ULC. All rights reserved